The company relies on third-party manufacturers to produce its products in compliance with contractual, regulatory, and quality control requirements, including current Good Manufacturing Practice (cGMP) standards. These manufacturing facilities are subject to inspections by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities. Failure to maintain manufacturing arrangements or compliance could result in delays to research, clinical trials, regulatory approvals, and commercialization, as well as potential product recalls or inability to meet demand. Contract manufacturers may encounter challenges such as resource constraints, labor disputes, or political instability, which could disrupt product supply. The company currently utilizes foreign contract research organizations (CROs) and contract manufacturing organizations (CMOs), including WuXi AppTec (Hong Kong) Limited, for manufacturing and development activities. Foreign CMOs may be impacted by U.S. legislation, sanctions, trade restrictions, and other regulatory requirements, potentially increasing costs or limiting material availability. The recently enacted BIOSECURE Act restricts U.S. federal agencies from contracting with companies that use biotechnology equipment or services from certain foreign biotechnology companies, which may affect the industry and the company's ability to obtain government contracts or funding.
Septerna Inc's Comment on Supply Chain
The company relies on third-party manufacturers to produce its products in compliance with contractual, regulatory, and quality control requirements, including current Good Manufacturing Practice (cGMP) standards. These manufacturing facilities are subject to inspections by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities. Failure to maintain manufacturing arrangements or compliance could result in delays to research, clinical trials, regulatory approvals, and commercialization, as well as potential product recalls or inability to meet demand. Contract manufacturers may encounter challenges such as resource constraints, labor disputes, or political instability, which could disrupt product supply. The company currently utilizes foreign contract research organizations (CROs) and contract manufacturing organizations (CMOs), including WuXi AppTec (Hong Kong) Limited, for manufacturing and development activities. Foreign CMOs may be impacted by U.S. legislation, sanctions, trade restrictions, and other regulatory requirements, potentially increasing costs or limiting material availability. The recently enacted BIOSECURE Act restricts U.S. federal agencies from contracting with companies that use biotechnology equipment or services from certain foreign biotechnology companies, which may affect the industry and the company's ability to obtain government contracts or funding.
Sources:
Septerna Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Septerna Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
